Company: LIMN
Filing Date: 2025-07-28
Form Type: S-1/A
Source: 0001410578-25-001518
Chunk: 300

Company: Liminatus Pharma, Inc.
Filing Date: 2025-07-28
Form: S-1/A
Chunk 300
---
 to make up to threedemands, excluding Form S-3 demands, that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the Company’s completion of its initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Underwriting Agreement The underwriters are entitled to an underwriting discount of 2% (or $ 5,520,000) of the gross proceeds of the IPO and deferred underwriting discount of 3.5% (or $ 9,660,000) of the gross proceeds of the IPO upon the completion of the Company’s initial Business Combination. On October 11, 2023, the Company executed a Fee Reduction Agreement with the underwriters to reduce the deferred underwriting discount of $ 9,660,000to $ 8,000,000in the event that the business combination with Liminatus is consummated. Pursuant to the terms of the agreement, the reduced deferred underwriting discount shall be payable by the Company to the underwriters in $ 1,000,000cash and $ 7,000,000of the common equity securities of the public entity that survives the transaction. As of March 31, 2025, the deferred underwriting discount of $ 9,660,000has not been reduced to $ 8,000,000because the release of the payable will occur upon the consummation of the business combination with Liminatus, which occurred on April 30, 2025. Upon the consummation of the Business Combination, $ 9,160,000in deferred underwriting fees were settled, of which $ 7,000,000will be settled in common shares of the combined company upon the earlier of (i) 180 daysfrom the consummation of the Business Combination, and (ii) the Company’s next share offering, $ 500,000was settled in cash and $ 1,660,000was waived and no longer payable. The remaining $ 500,000will be settled upon the earlier of the consummation of the combined company’s next share offering, or in six monthsfrom the date of the business combination. Capital Markets Advisory Agreement On July 19, 2024, the Company entered into a capital markets advisory agreement with Benjamin Securities, Inc. and Liminatus Pharma, LLC to perform certain services for the Company and Limin